Table 2 Microbiologic data for subjects with diagnoses of RPLI, PNA, and microbiologically confirmed PNA

RPLI (+)

Rate of Documented RPLI, n (%) (total cohort)

21 (28.0)

   History of PNA in prior 180 days, n (%)

2 (9.5)

Time between PTE and RPLI (days), median (IQR)

2 (1,3)

PNA (+)

Rate of Documented PNA, n (%) (total cohort)

18 (24.0)

   History of PNA in prior 180 days, n (%)

2 (11.1)

Rate of Microbiologically Confirmed PNA, n (%) (total cohort)

5 (6.7)

   Time between PTE and PNA, median (IQR)

5 (3,5)

Diagnostic Sampling

Rate of Diagnostic Sampling Performed, n (%)

8 (10.7)

Rate of Positive BAL/NBBAL*, n (%)

5 (62.5)

   Haemophilus parainfluenzae, n (%)

1 (20.0)

   Pseudomonas aeruginosa, n (%)

2 (40.0)

   Staphylococcus aureus, n (%)

2 (40.0)

   Methicillin-resistant Staphylococcus aureus (MRSA), n (%)

1 (50.0)

Postoperative Antibiotics in Post-PTE PNA Subjects

Postoperative Antibiotics, n (%)

   Cefepime

3 (60.0)

   Ceftriaxone

1 (20.0)

   Piperacillin-tazobactam

1 (20.0)

   Vancomycin

1 (20.0)

Duration of Antibiotics in Days, median (IQR)

7.5 (2.5,8.8)